Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
101 hedge funds and large institutions have $130M invested in Enzo Biochem, Inc. in 2018 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 32 increasing their positions, 31 reducing their positions, and 11 closing their positions.
5,767% more call options, than puts
Call options by funds: $352K | Put options by funds: $6K
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
4% more funds holding
Funds holding: 97 → 101 (+4)
3% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
22% less capital invested
Capital invested by funds: $166M → $130M (-$35.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
+$3.48M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.57M |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$1.14M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$509K |
| 5 |
AG
Algert Global
San Francisco,
California
|
+$391K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$3.96M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.57M |
| 3 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
-$897K |
| 4 |
EGA
Evermore Global Advisors
Summit,
New Jersey
|
-$843K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$702K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
101
Credit Suisse
Zurich,
Switzerland
| – | -$66K | -12,887 | Closed |
|
102
SG Americas Securities
New York
| – | -$61K | -11,692 | Closed |
|
|
CF
103
Centaurus Financial
Anaheim,
California
| – | -$5K | -1,000 | Closed |
|
|
PIA
104
Piedmont Investment Advisors
Durham,
North Carolina
| – | -$4K | -765 | Closed |
|
|
TWA
105
TCI Wealth Advisors
Tucson,
Arizona
| – | -$2K | -346 | Closed |
|
106
Fidelity Investments
Boston,
Massachusetts
| – | +$5 | +1 | New |
|
|
TRCT
107
Tower Research Capital (TRC)
New York
| – | +$127 | +28 | New |
|
ENZ Hedge Fund Activity: Q3 2018 in Review
101 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q3 2018, worth a combined $130M — down 22% from $166M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ENZ positions and 11 closed out — a net gain of 4 holders — while 32 added to existing stakes and 31 trimmed.
The largest buyer was Roumell Asset Management, opening a new position worth an estimated $3.48M. The largest seller was Gilder Gagnon Howe & Co, exiting entirely with an estimated $3.96M sold.
- 101 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q3 2018, up from 97 in Q2 2018.
- Funds reported $130M of Enzo Biochem, Inc. stock for Q3 2018, down 22% quarter-over-quarter.
- 15 funds opened new Enzo Biochem, Inc. positions in Q3 2018 and 11 closed out, a net change of +4 holders.
- The largest Enzo Biochem, Inc. buyer in Q3 2018 was Roumell Asset Management, an estimated $3.48M added.
- The largest Enzo Biochem, Inc. seller in Q3 2018 was Gilder Gagnon Howe & Co, an estimated $3.96M sold.
Based on aggregated 13F filings for Q3 2018.